19628 Federal Register / Vol. 61, No. 86 / Thursday, May 2, 1996 / Notices

has not imposed similar limitations on

the securities brokerage activities of

bank holding companies. See 12 CFR

225.25(b)(15). BNY also contends that

riskless principal transactions do not

involve the potential conflicts of

interests, unsound banking practices

and other adverse effects that are sought

to be addressed by the Section 20

Firewalls. Furthermore, BNY asserts

that compliance with the section 20

Firewalls would place a bank holding

company engaged in riskless principal

transactions at a competitive

disadvantage to other broker-dealers

engaged in such activity.

Company, however, would conduct

its riskless principal activities subject to

the other conditions established by the

Board in previous orders, including

those conditions that are designed to

assure that a bank holding company’s

riskless principal activities do not

constitute the underwriting, public sale,

or distribution of securities for purposes

of the Glass-Steagall Act. See Bankers

Trust; J.P. Morgan; BankAmerica

Corporation, 79 Fed. Res. Bull. 1163

(1993). For example, Company would

engage in riskless principal transactions

only in the secondary market and would

not engage in riskless principal

transactions for any security carried in

its inventory. Company also would not

act as riskless principal with respect to

registered investment company

securities or the securities of investment

companies advised by BNY or any of its

affiliates.

In order to approve the proposal, the

Board must determine that the proposed

activities to be conducted by BNY ‘‘can

reasonably be expected to produce

benefits to the public, such as greater

convenience, increased competition, or

gains in efficiency, that outweigh

possible adverse effects, such as undue

concentration of resources, decreased or

unfair competition, conflicts of

interests, or unsound banking

practices.’’ 12 U.S.C. 1843(c)(8). BNY

believes that the proposal would

produce public benefits that outweigh

any potential adverse effects. In

particular, BNY maintains that the

proposal would increase competition for

the proposed services.

In publishing the proposal for

comment, the Board does not take a

position on issues raised by the

proposal. Notice of the proposal is

published solely to seek the views of

interested persons on the issues

presented by the application and does

not represent a determination by the

Board that the proposal meets, or is

likely to meet, the standards of the BHC

Act. Any comments or requests for

hearing should be submitted in writing

and received by William W. Wiles,

Secretary, Board of Governors of the

Federal Reserve System, Washington,

D.C. 20551, not later than May 28, 1996.

Any request for a hearing on this

application must, as required by §

262.3(e) of the Board’s Rules of

Procedure (12 CFR 262.3(e)), be

accompanied by a statement of the

reasons why a written presentation

would not suffice in lieu of a hearing,

identifying specifically any questions of

fact that are in dispute, summarizing the

evidence that would be presented at a

hearing, and indicating how the party

commenting would be aggrieved by

approval of the proposal.

This application may be inspected at

the offices of the Board of Governors or

the Federal Reserve Bank of New York.

Board of Governors of the Federal Reserve

System, April 26, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–10907 Filed 5–1–96; 8:45 am]

BILLING CODE 6210–01–F

Change in Bank Control Notices;

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies;

Correction

This notice corrects a notice (FR Doc.

96-9809) published on pages 17704 and

17705 of the issue for April 22, 1996.

Under the Federal Reserve Bank of

Atlanta heading, the entry for Bradley

County Financial Corp., Cleveland,

Ohio, is revised to read as follows:

1. Bradley County Financial Corp.,

Cleveland, Tennessee; to engage de novo

through its subsidiary, Tennessee

Financial Services, Inc., Cleveland,

Tennessee, in consumer finance and

insurance agency activities, pursuant to

§§ 225.25(b)(1)(i), 225.25(b)(8)(i), and

225.25(b)(8)(ii) of the Board’s Regulation

Y. The proposed activities will be

conducted throughout the States of

Tennessee and Georgia.

Comments on this application must

be received by May 6, 1996.

Board of Governors of the Federal Reserve

System, April 26, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–10908 Filed 5–1–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Institute for Occupational

Safety and Health Meeting

The National Institute for

Occupational Safety and Health

(NIOSH) of the Centers for Disease

Control and Prevention (CDC)

announces the following meeting.

Name: Review of the research protocol for

the study: ‘‘Evaluation of Prevention

Strategies to Reduce Back Pain and Injury

Among Nursing Home Workers.’’

Time and Date: 1 p.m.–5 p.m., June 5,

1996.

Place: Suncrest Facility, Large Conference

Room, NIOSH, CDC, 3040 University

Avenue, Morgantown, West Virginia 26505–

2888.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 60 people.

Purpose: The purpose of this meeting is to

obtain comments and input regarding the

technical and scientific merits of the study,

‘‘Evaluation of Prevention Strategies to

Reduce Back Pain and Injury Among Nursing

Home Workers,’’ being conducted by NIOSH.

The purpose of the proposed research is to

evaluate lifting equipment and medical

management programs for their effectiveness

in reducing the incidence, cost, and

subsequent disability associated with workrelated injuries and reports of pain.

Participants will review the proposed study

protocol, provide recommendations for

scientific changes, and provide advice to

NIOSH on the conduct of the study.

Viewpoints and suggestions from industry,

labor, academia, other government agencies

and the public are invited. Written comments

will be part of the review, and should be

received by the contact person listed below

no later than May 21, 1996.

Contact Person for Additional Information:

James W. Collins, NIOSH, CDC, 1095

Willowdale Road, M/S 1133, Morgantown,

West Virginia 26505–2888, telephone 304/

285–5998.

Dated: April 25, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 96–10884 Filed 5–1–96; 8:45 am]

BILLING CODE 4160–19–M

Health Care Financing Administration

[R–131]

Agency Information Collection

Activities: Proposed Collection;

Comment Request

In compliance with the requirement

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the
Federal Register / Vol. 61, No. 86 / Thursday, May 2, 1996 / Notices 19629

Health Care Financing Administration

(HCFA), Department of Health and

Human Services, is publishing the

following summary of proposed

collections for public comment.

Interested persons are invited to send

comments regarding the burden

estimate or any other aspect of this

collection of information, including any

of the following subjects: (1) The

necessity and utility of the proposed

information collection for the proper

performance of the agency’s functions;

(2) the accuracy of the estimated

burden; (3) ways to enhance the quality,

utility, and clarity of the information to

be collected; and (4) the use of

automated collection techniques or

other forms of information technology to

minimize the information collection

burden.

Type of Information Collection

Request: Reinstatement, without change,

of a previously approved collection for

which approval has expired; Title of

Information Collection: Information

Collection Requirements in BPD–458–F,

Section 411.408(d)(2) and (f); Form No.:

HCFA–R–131; Use: Physicians who do

not accept assignment may bill a patient

for services denied by Medicare as ‘‘not

reasonable and necessary,’’ if they

informed the patient, prior to furnishing

the services, that Medicare was likely to

deny part B payments for services and

the patient, after being so informed,

agrees to pay for the services.

Frequency: On occasion; Affected

Public: Individuals or Households;

Number of Respondents: 237,322; Total

Annual Responses: 925,904; Total

Annual Hours Requested: 115,738.

To request copies of the proposed

paperwork collections referenced above,

call the Reports Clearance Office on

(410) 786–1326. Written comments and

recommendations for the proposed

information collections should be sent

within 60 days of this notice directly to

the HCFA Paperwork Clearance Officer

designated at the following address:

HCFA, Office of Financial and Human

Resources Management Planning and

Analysis Staff, Attention: Louis Blank,

Room C2–26–17, 7500 Security

Boulevard, Baltimore, Maryland 21244–

1850.

Dated: April 24, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis

Staff, Office of Financial and Human

Resources.

[FR Doc. 96–10864 Filed 5–1–96; 8:45 am]

BILLING CODE 4120–03–P

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies, and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS

(Formerly: National Institute on Drug

Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and

will be omitted from the monthly listing

thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh, Division of Workplace

Programs, Room 13A–54, 5600 Fishers

Lane, Rockville, Maryland 20857; Tel.:

(301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

Aegis Analytical Laboratories, Inc. 624

Grassmere Park Rd., Suite 21,

Nashville, TN 37211, 615–331–5300

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931/205–263–5745

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

22021, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–

583–2787

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–227–2783

(formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Bayshore Clinical Laboratory, 4555 W.

Schroeder Dr., Brown Deer, WI 53223,

414–355–4444/800–877–7016

Cedars Medical Center, Department of

Pathology, 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5810

Centinela Hospital Airport Toxicology

Laboratory, 9601 S. Sepulveda Blvd.

Los Angeles, CA 90045, 310–215–

6020

Clinical Reference Lab, 11850 West 85th

St., Lenexa, KS 66214, 800–445–6917

CompuChem Laboratories, Inc., 3308

Chapel Hill/Nelson Hwy., Research

Triangle Park, NC 27709, 919–549–

8263/800–833–3984 (Formerly:

CompuChem Laboratories, Inc., A

Subsidiary of Roche Biomedical

Laboratory, Roche CompuChem

Laboratories, Inc., A Member of the

Roche Group)

CORNING Clinical Laboratories, 4771

Regent Blvd., Irving, TX 75063, 800–

526–0947 (formerly: Damon Clinical

Laboratories, Damon/MetPath)

CORNING Clinical Laboratories, 875

Greentree Rd., 4 Parkway Ctr.,

Pittsburgh, PA 15220–3610, 800–284–

7515 (formerly: Med-Chek

Laboratories, Inc., Med-Chek/Damon,

MetPath Laboratories)

CORNING Clinical Laboratories, 24451

Telegraph Rd., Southfield, MI 48034,

800–444–0106, ext. 650 (formerly:

HealthCare/Preferred Laboratories,

Health Care/MetPath)

CORNING Clinical Laboratories Inc.,

1355 Mittel Blvd., Wood Dale, IL